End Stage Renal Disease (ESRD) Drug Market Insights: In-Depth Look at Growth Trends, Market Size, and Opportunities for 2025-2034
Discover trends, market shifts, and competitive outlooks for the end stage renal disease (esrd) drug industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
#What Is the Current and Projected Market Size of the End Stage Renal Disease (ESRD) Drug Market Through 2034?
The market size for drugs catering to end stage renal disease (ESRD) has swiftly expanded in the past few years. It is set to increase from a substantial $131.41 billion in 2024 to an impressive $149.88 billion in 2025, with a compound annual growth rate (CAGR) of 14.1%. The remarkable growth in the historic duration can be ascribed to a rise in the occurrence of end stage renal disease, the aging population, enhanced access to healthcare services, governmental initiatives and policies, along with an increased uptake of renal replacement therapies.
The market size of drugs for end stage renal disease (ESRD) is projected to experience a swift rise in the imminent years. Its expected growth to $268.44 billion in 2029 at a compound annual growth rate (CAGR) of 15.7% can be ascribed to factors such as developing therapies, innovation in drugs, escalated healthcare spending, the growing global prevalence of chronic kidney disorders, individualized medication approaches, regulatory aid, and swift approvals. The forecast period is likely to be characterized by major trends including a rising incidence of end stage renal disease, progress in treatment methods, an increased focus on precision medicine, the creation of combined therapies, and the incorporation of technology in healthcare.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
What External and Internal Drivers Are Contributing to the Growth of the End Stage Renal Disease (ESRD) Drug Market?
The increase in obesity and diabetes prevalence is projected to accelerate the expansion of the end-stage renal disease (ESRD) drug market. Obesity refers to unusual or excessive fat accumulation that raises health risks, while diabetes is a long-term disorder that occurs when the body either fails to produce enough insulin or can’t effectively use the generated insulin. In the context of renal disease, maintaining fluid and electrolyte balance, controlling blood pressure, and removing waste products through dialysis can enhance overall health leading to possible weight loss and improved control of blood sugar levels. For example, in March 2022, as per World Obesity, an American membership organization that represents national and regional groups committed to the research and treatment of obesity, the worldwide obesity count is projected to jump to 892 million by 2025, increasing further to 1,025 million in 2030. Moreover, in February 2023, the national health service of UK, a publicly funded healthcare system, estimated that by 2030, about 5.5 million people in the UK might have diabetes, which would affect almost 9% of its total population. Therefore, the escalation in obesity and diabetes instances will positively influence the demand for end-stage renal disease (ESRD) drugs.
What Segment Types Define the End Stage Renal Disease (ESRD) Drug Market Structure?
The end stage renal disease (ESRD) drug market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the End Stage Renal Disease (ESRD) Drug Market?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Long-Term Trends Are Transforming the Competitive Landscape of the End Stage Renal Disease (ESRD) Drug Market?
In the end-stage renal disease (ESRD) drug market, one of the key strategies for gaining traction is product innovation. Large-scale companies in this market are putting their focus on creating unique solutions to keep up with the competition. For instance, a notable event in April 2022 saw the US Food and Drug Administration (FDA) acknowledge the New Drug Application (NDA) from GlaxoSmithKline PLC, a pharmaceutical and biotechnology company from the UK. The drug in question, daprodustat, an orally taken hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), holds potential in treating those suffering from chronic kidney disease anemia (CKD). What sets this new product apart is the utilization of exclusive, Nobel prize-winning science which demonstrates how cells adapt and respond to the presence of oxygen.
View the full report here:
What Is the Definition of the End Stage Renal Disease (ESRD) Drug Market?
End stage renal disease (ESRD) drug is a drug used to treat a medical illness in which a person’s kidneys stop working permanently, requiring a kidney transplant or a regular regimen of long-term dialysis to protect life. It is crucial in treating and preventing secondary problems in individuals with chronic renal disease (CKD).
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9437
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
